Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spondyloarthropathies: progress and challenges.

Peggy Jacques1, Herman Mielants, Martine De Vos

  • 1University Hospital Ghent, Department of Rheumatology, Ghent, Belgium.

Best Practice & Research. Clinical Rheumatology
|May 6, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Value and Treatment Responsiveness of Ultrasound Features in correlation with clinical findings in Early Peripheral Spondyloarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Preventing MALT1-mediated CYLD cleavage induces intestinal dysbiosis and reduces EAE severity.

EMBO reports·2026
Same author

Structural and mechanistic insights into the constitutive Themis-Grb2 complex in T cell signalling.

Nature communications·2026
Same author

Efgartigimod in Sjögren's disease: a phase 2, randomised, placebo-controlled, parallel-group, double-blinded, proof-of-concept study (RHO).

Annals of the rheumatic diseases·2026
Same author

Barrier breakdown: insights into the skin-gut axis in psoriatic arthritis.

Trends in immunology·2026
Same author

In vivo modeling of human γδ T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 Vδ2 T cell development.

Cell reports·2026
Same journal

The young adult with Juvenile Idiopathic Arthritis (JIA): A clinical review of transition, complications, and psychosocial management.

Best practice & research. Clinical rheumatology·2026
Same journal

Impact of fatigue on rheumatic diseases: Current perspectives.

Best practice & research. Clinical rheumatology·2026
Same journal

Pneumocystis prophylaxis in rheumatic disease.

Best practice & research. Clinical rheumatology·2026
Same journal

Cutaneous manifestations in myositis syndromes.

Best practice & research. Clinical rheumatology·2026
Same journal

Systemic sclerosis: A comprehensive systematic review of global epidemiology, sex and ethnic disparities, disease burden, and organ-specific involvement.

Best practice & research. Clinical rheumatology·2026
Same journal

Alopecia across the spectrum of rheumatic disease.

Best practice & research. Clinical rheumatology·2026
See all related articles

Spondyloarthropathies (SpA) pathogenesis remains unclear, particularly inflammation origins and gut-joint links. While tumor necrosis factor (TNF) blockers manage SpA symptoms, their impact on new bone formation and extra-articular issues requires further investigation.

Area of Science:

  • Rheumatology
  • Immunology
  • Genetics

Background:

  • Spondyloarthropathies (SpA) are rheumatic disorders frequently presenting with extra-articular manifestations.
  • Despite extensive research, key questions regarding SpA pathogenesis and treatment remain unresolved.
  • Understanding the precise inflammatory sites and genetic links in SpA is crucial.

Purpose of the Study:

  • To address unresolved questions in spondyloarthropathies pathogenesis and treatment.
  • To investigate the origin of inflammation within joints in SpA.
  • To explore the genetic basis of the gut-joint inflammation link and evaluate TNF blockers' efficacy.

Main Methods:

  • Review of current literature on spondyloarthropathies.
  • Analysis of inflammatory processes in joints (enthesitis, synovitis, bone marrow).

Related Experiment Videos

  • Examination of genetic factors contributing to gut-joint inflammation and TNF blocker effects.

    • Main Results:

    • The exact site of inflammation initiation in SpA joints is debated.
    • Genetic predisposition plays a role in the connection between gut and joint inflammation.
    • TNF blockers effectively modulate SpA symptoms, but their effect on new bone formation and extra-articular manifestations varies.

    Conclusions:

    • Further research is needed to fully elucidate SpA pathogenesis.
    • The efficacy of different TNF blockers in managing SpA's diverse manifestations needs clarification.
    • Targeting specific inflammatory pathways may improve SpA treatment outcomes.